Lucia Musumeci1, Marijke J Kuijpers1, Karen Gilio1, Alexandre Hego1, Emilie Théâtre1, Lisbeth Maurissen1, Maud Vandereyken1, Catia V Diogo1, Christelle Lecut1, William Guilmain1, Ekaterina V Bobkova1, Johannes A Eble1, Russell Dahl1, Pierre Drion1, Justin Rascon1, Yalda Mostofi1, Hongbin Yuan1, Eduard Sergienko1, Thomas D Y Chung1, Marc Thiry1, Yotis Senis1, Michel Moutschen1, Tomas Mustelin1, Patrizio Lancellotti1, Johan W M Heemskerk1, Lutz Tautz2, Cécile Oury2, Souad Rahmouni2. 1. From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.). 2. From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.). srahmouni@ulg.ac.be cecile.oury@ulg.ac.be tautz@sanfordburnham.org.
Abstract
BACKGROUND: A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. A better understanding of the molecular mechanisms leading to platelet activation is important for the development of improved therapies. Recently, protein tyrosine phosphatases have emerged as critical regulators of platelet function. METHODS AND RESULTS: This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated by the collagen receptor glycoprotein VI and the C-type lectin-like receptor 2. DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism compared with wild-type mice and showed severely impaired thrombus formation on ferric chloride-induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of phospholipase Cγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen- and C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells. CONCLUSIONS: DUSP3 plays a selective and essential role in collagen- and C-type lectin-like receptor 2-mediated platelet activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is the first time a protein tyrosine phosphatase, implicated in platelet signaling, has been targeted with a small-molecule drug.
BACKGROUND: A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. A better understanding of the molecular mechanisms leading to platelet activation is important for the development of improved therapies. Recently, protein tyrosine phosphatases have emerged as critical regulators of platelet function. METHODS AND RESULTS: This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated by the collagen receptor glycoprotein VI and the C-type lectin-like receptor 2. DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism compared with wild-type mice and showed severely impaired thrombus formation on ferric chloride-induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of phospholipase Cγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen- and C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells. CONCLUSIONS: DUSP3 plays a selective and essential role in collagen- and C-type lectin-like receptor 2-mediated platelet activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is the first time a protein tyrosine phosphatase, implicated in platelet signaling, has been targeted with a small-molecule drug.
Authors: Ekaterina V Bobkova; Wallace H Liu; Sharon Colayco; Justin Rascon; Stefan Vasile; Carlton Gasior; David A Critton; Xochella Chan; Russell Dahl; Ying Su; Eduard Sergienko; Thomas D Y Chung; Tomas Mustelin; Rebecca Page; Lutz Tautz Journal: ACS Med Chem Lett Date: 2011-02 Impact factor: 4.345
Authors: B Nieswandt; C Brakebusch; W Bergmeier; V Schulte; D Bouvard; R Mokhtari-Nejad; T Lindhout; J W Heemskerk; H Zirngibl; R Fässler Journal: EMBO J Date: 2001-05-01 Impact factor: 11.598
Authors: Imke C A Munnix; Marijke J E Kuijpers; Jocelyn Auger; Christella M L G D Thomassen; Peter Panizzi; Marc A M van Zandvoort; Jan Rosing; Paul E Bock; Steve P Watson; Johan W M Heemskerk Journal: Arterioscler Thromb Vasc Biol Date: 2007-08-30 Impact factor: 8.311
Authors: Markus Bender; Frauke May; Viola Lorenz; Ina Thielmann; Ina Hagedorn; Brenda A Finney; Timo Vögtle; Katharina Remer; Attila Braun; Michael Bösl; Steve P Watson; Bernhard Nieswandt Journal: Arterioscler Thromb Vasc Biol Date: 2013-02-28 Impact factor: 8.311
Authors: Frauke May; Ina Hagedorn; Irina Pleines; Markus Bender; Timo Vögtle; Johannes Eble; Margitta Elvers; Bernhard Nieswandt Journal: Blood Date: 2009-07-29 Impact factor: 22.113
Authors: Yke Jildouw Arnoldussen; Petra I Lorenzo; Maria E Pretorius; Håkon Waehre; Bjørn Risberg; Gunhild M Maelandsmo; Håvard E Danielsen; Fahri Saatcioglu Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701